Fingerprint
Dive into the research topics of 'Phase i trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase i trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
Tufia C. Haddad, Antonino D’Assoro, Vera Suman, Mateusz Opyrchal, Prema Peethambaram, Minetta C. Liu, Matthew P. Goetz, James N. Ingle
Research output: Contribution to journal › Article › peer-review
23
Scopus
citations